Dipna Pharmachem Ltd Stock Price Today (NSE: DPL)
Fundamental Score
Dipna Pharmachem Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Dipna Pharmachem Ltd share price today is ₹8.02, down 2.59% on NSE/BSE as of 30 March 2026. Dipna Pharmachem Ltd (DPL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹40.40 (Cr). The 52-week high for DPL share price is ₹26.31 and the 52-week low is ₹7.45. At a P/E ratio of 19.71x, DPL is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 2.55% and a debt-to-equity ratio of 0.23.
Dipna Pharmachem Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Dipna Pharmachem Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Dipna Pharmachem Share Price: A ROCE Efficiency Analysis
The pharmaceutical sector, often driven by innovation and regulatory hurdles, demands operational excellence for sustained profitability. Within this context, this analysis explores the financial standing of Dipna Pharmachem Ltd, focusing primarily on Return on Capital Employed (ROCE) efficiency. The current Dipna Pharmachem share price stands at ₹12.71, with a Price-to-Earnings (PE) ratio of 19.71 and a ROCE of 6.64%. This analysis is part of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra, designed to provide an objective assessment of the company's financial health.
A crucial metric for evaluating operational efficiency, ROCE indicates how effectively a company utilizes its capital to generate profits. Dipna Pharmachem's ROCE of 6.64% suggests that for every ₹100 of capital employed, the company generates ₹6.64 in earnings before interest and taxes. While this figure provides a baseline, it is imperative to contextualize it within the broader industry landscape.
Compared to sector peers, the ROCE figure potentially signals areas for improvement. For instance, examining
Mankind Pharma Ltd reveals potentially different approaches to capital allocation and operational management. Assessing the perceived quality of management, and its influence on strategic decisions regarding pricing, cost control, and resource allocation, can provide valuable insight into the variance in operational efficiency across peer companies like Mankind Pharma Ltd, Smruthi Organics Ltd, and Balaxi Pharmaceuticals Ltd.A lower ROCE, such as the 6.64% exhibited by Dipna Pharmachem, can potentially impact the company’s long-term competitive advantage, or "moat." A higher ROCE allows a company to reinvest more aggressively in growth opportunities, innovation, and market share acquisition, thereby strengthening its moat. Conversely, a lower ROCE might indicate a weaker competitive position, making it more susceptible to market pressures. Further investigation into the company's operational strategies, capital expenditure plans, and competitive environment is warranted to fully understand the implications of its current ROCE. This analysis is purely observational and does not constitute any investment recommendation.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Dipna Pharmachem Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of DPL across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Attractive Valuation (P/E: 19.71 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (314.71%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Consistent Growth Track Record (32.54% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (74.47% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.23)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
9 factors identified
Below-Average Return on Equity (2.55%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.64%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (2.46%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Revenue Contraction (-18.85%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Earnings Growth (-41.72% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Weak Interest Coverage (2.43x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-35.27 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (9.98%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Dipna Pharmachem Ltd Financial Statements
Comprehensive financial data for Dipna Pharmachem Ltd including income statement, balance sheet and cash flow
About DPL (Dipna Pharmachem Ltd)
Dipna Pharmachem Ltd is a dynamic and innovative pharmaceutical company that acts as a vital bridge in the complex global supply chain. Situated in the heart of Ahmedabad, India, D...PL specializes in the procurement, distribution, and export of an extensive range of pharmaceutical necessities. From the foundational building blocks of drug development to the crucial components that ensure formulation stability, DPL provides a comprehensive portfolio tailored to meet the diverse needs of the pharmaceutical industry. The company prides itself on a dedication to sourcing high-quality materials, fostering strong relationships with both suppliers and customers, and maintaining a meticulous approach to regulatory compliance, solidifying its position as a trusted partner in the ever-evolving landscape of pharmaceutical manufacturing. At the core of Dipna Pharmachem's operations lies a robust commitment to providing a diverse selection of essential pharmaceutical ingredients. DPL meticulously sources and supplies active pharmaceutical ingredients (APIs) that are the core of many medications. Furthermore, the company offers an array of crucial industrial chemicals, meticulously selected excipients that serve to enhance drug delivery and stability, high-purity solvents that facilitate critical chemical reactions, complex formulations that need specific elements and unique intermediates that allow for innovation in various pharmaceutical synthesis pathways. This multifaceted product offering enables DPL to cater to a broad spectrum of clients within the pharmaceutical sector, ranging from research institutions to large-scale manufacturing facilities, creating a wide area of clientele and need. Founded in 2011, Dipna Pharmachem Ltd has rapidly established itself as a reliable and agile player in the Indian pharmaceutical market. Driven by a customer-centric philosophy, DPL strives to exceed expectations through responsive service, competitive pricing, and a commitment to delivering superior products. The company leverages its strategic location in Ahmedabad to efficiently manage its import, trade, and export operations, ensuring timely delivery to clients both domestically and internationally. With a focus on continuous improvement and adaptation to the evolving needs of the pharmaceutical industry, Dipna Pharmachem Ltd is poised to continue its growth trajectory and solidify its position as a trusted partner for pharmaceutical companies worldwide.
Company Details
Key Leadership
Latest News
DPL Share Price: Frequently Asked Questions
What is the current share price of Dipna Pharmachem Ltd (DPL)?
As of 30 Mar 2026, 12:05 pm IST, Dipna Pharmachem Ltd share price is ₹8.02. The DPL stock has a market capitalisation of ₹40.40 (Cr) on NSE/BSE.
Is DPL share price Overvalued or Undervalued?
DPL share price is currently trading at a P/E ratio of 19.71x, compared to the industry average of 31.77x. Based on this relative valuation, the Dipna Pharmachem Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of DPL share price?
The 52-week high of DPL share price is ₹26.31 and the 52-week low is ₹7.45. These values are updated daily from NSE/BSE price data.
What factors affect the Dipna Pharmachem Ltd share price?
Key factors influencing DPL share price include quarterly earnings growth (Sales Growth: -18.85%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Dipna Pharmachem Ltd a good stock for long-term investment?
Dipna Pharmachem Ltd shows a 5-year Profit Growth of 74.47% and an ROE of 2.55%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.23 before investing in DPL shares.
How does Dipna Pharmachem Ltd compare with its industry peers?
Dipna Pharmachem Ltd competes with major peers in the Pharmaceuticals. Investors should compare DPL share price P/E of 19.71x and ROE of 2.55% against the industry averages to determine competitive standing.
What is the P/E ratio of DPL and what does it mean?
DPL share price has a P/E ratio of 19.71x compared to the industry average of 31.77x. Investors pay ₹20 for every ₹1 of annual earnings.
How is DPL performing according to Bull Run's analysis?
DPL has a Bull Run fundamental score of 39.4/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does DPL belong to?
DPL operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Dipna Pharmachem Ltd share price.
What is Return on Equity (ROE) and why is it important for DPL?
DPL has an ROE of 2.55%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Dipna Pharmachem Ltd generates profits from shareholders capital.
How is DPL debt-to-equity ratio and what does it indicate?
DPL has a debt-to-equity ratio of 0.23, which indicates conservative financing with low financial risk.
What is DPL dividend yield and is it a good dividend stock?
DPL offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Dipna Pharmachem Ltd shares.
How has DPL share price grown over the past 5 years?
DPL has achieved 5-year growth rates of: Sales Growth 32.54%, Profit Growth 74.47%, and EPS Growth -41.72%.
What is the promoter holding in DPL and why does it matter?
Promoters hold 9.98% of DPL shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Dipna Pharmachem Ltd.
What is DPL market capitalisation category?
DPL has a market capitalisation of ₹40 crores, placing it in the Small-cap category.
How volatile is DPL stock?
DPL has a beta of N/A. A beta > 1 suggests the Dipna Pharmachem Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is DPL operating profit margin trend?
DPL has a 5-year average Operating Profit Margin (OPM) of 2.46%, indicating the company's operational efficiency.
How is DPL quarterly performance?
Recent quarterly performance shows Dipna Pharmachem Ltd YoY Sales Growth of -18.85% and YoY Profit Growth of 314.71%.
What is the institutional holding pattern in DPL?
DPL has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Dipna Pharmachem Ltd stock.